

Mark A J Gorris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8914529/publications.pdf>

Version: 2024-02-01

34
papers

1,606
citations

623734

14
h-index

477307

29
g-index

39
all docs

39
docs citations

39
times ranked

3272
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuronal medium that supports basic synaptic functions and activity of human neurons in vitro. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E2725-34.	7.1	317
2	Migrating into the Tumor: a Roadmap for T Cells. Trends in Cancer, 2017, 3, 797-808.	7.4	230
3	Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment. Journal of Immunology, 2018, 200, 347-354.	0.8	181
4	Predicting the functional states of human iPSC-derived neurons with single-cell RNA-seq and electrophysiology. Molecular Psychiatry, 2016, 21, 1573-1588.	7.9	136
5	Generation of functional human serotonergic neurons from fibroblasts. Molecular Psychiatry, 2016, 21, 49-61.	7.9	115
6	Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines. Cancer Research, 2016, 76, 4332-4346.	0.9	93
7	Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent. Oncotarget, 2017, 8, 71371-71384.	1.8	85
8	Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer. , 2019, 7, 302.		72
9	Peptide-mediated delivery of therapeutic mRNA in ovarian cancer. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 141, 180-190.	4.3	62
10	The tumour microenvironment shapes dendritic cell plasticity in a human organotypic melanoma culture. Nature Communications, 2020, 11, 2749.	12.8	51
11	Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial. Cancer Immunology, Immunotherapy, 2020, 69, 477-488.	4.2	42
12	Human pDCs Are Superior to cDC2s in Attracting Cytolytic Lymphocytes in Melanoma Patients Receiving DC Vaccination. Cell Reports, 2020, 30, 1027-1038.e4.	6.4	29
13	Human blood myeloid and plasmacytoid dendritic cells cross activate each other and synergize in inducing NK cell cytotoxicity. Oncoimmunology, 2016, 5, e1227902.	4.6	26
14	Immunomodulatory aged neutrophils are augmented in blood and skin of psoriasis patients. Journal of Allergy and Clinical Immunology, 2021, 148, 1030-1040.	2.9	25
15	Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis. Frontiers in Immunology, 2021, 12, 768957.	4.8	22
16	Clusters of Tolerogenic B Cells Feature in the Dynamic Immunological Landscape of the Pregnant Uterus. Cell Reports, 2020, 32, 108204.	6.4	19
17	EpCAM-Binding DARPins for Targeted Photodynamic Therapy of Ovarian Cancer. Cancers, 2020, 12, 1762.	3.7	17
18	Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome. , 2022, 10, e004329.		15

#	ARTICLE	IF	CITATIONS
19	Immunological responses to adjuvant vaccination with combined CD1c ⁺ myeloid and plasmacytoid dendritic cells in stage III melanoma patients. <i>Oncolmmunology</i> , 2022, 11, .	4.6	14
20	Spontaneous Regression of Ovarian Carcinoma After Septic Peritonitis; A Unique Case Report. <i>Frontiers in Oncology</i> , 2018, 8, 562.	2.8	11
21	Spatial and Temporal Heterogeneity of Tumor-Infiltrating Lymphocytes in Advanced Urothelial Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 802877.	4.8	5
22	Preventive dendritic cell vaccination in healthy Lynch syndrome mutation carriers. <i>Annals of Oncology</i> , 2016, 27, vi362.	1.2	4
23	Immune cell composition in the endometrium of patients with a complete molar pregnancy: Effects on outcome. <i>Gynecologic Oncology</i> , 2021, 160, 450-456.	1.4	4
24	In-depth assessment of metastatic prostate cancer with high tumour mutational burden. <i>Annals of Oncology</i> , 2018, 29, viii274.	1.2	3
25	Challenges of Neoantigen Targeting in Lynch Syndrome and Constitutional Mismatch Repair Deficiency Syndrome. <i>Cancers</i> , 2021, 13, 2345.	3.7	3
26	Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype. <i>Oncolmmunology</i> , 2022, 11, .	4.6	3
27	Natural dendritic cell vaccinations generate immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2019, 30, v480.	1.2	2
28	Correlates of response to anti-PD-1 immune checkpoint blockade (ICB) in mismatch repair proficient (MMRp) and deficient (MMRd) patients (pts) with metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 5036-5036.	1.6	2
29	Differences in local immune cell landscape between Q fever and atherosclerotic abdominal aortic aneurysms identified by multiplex immunohistochemistry. <i>ELife</i> , 2022, 11, .	6.0	2
30	The different moods of human serotonergic neurons. <i>Molecular Psychiatry</i> , 2016, 21, 3-3.	7.9	1
31	<sc>PD-1</sc> in gestational trophoblastic disease: an antibody evaluation. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 0, , .	2.8	1
32	Which angiosarcoma subtypes may benefit from immunotherapy?. <i>Journal of Clinical Oncology</i> , 2022, 40, 11572-11572.	1.6	1
33	Intratumoral T cell depletion following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer is associated with poor clinical outcome. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	4.2	1
34	Activated adaptive immune system in dissected bicuspid aortic valve aortas: trigger for dissection?. <i>European Heart Journal</i> , 2020, 41, .	2.2	0